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Abstract  
The prevalence of antibiotic resistant microbes has led to a call for new antibiotics 
development.  Due to the irresponsible practices of the medical community in prescribing 
antibiotics, much of the demand for new antibiotics is suspect.  I argue that the social 
contract, which properly includes human relationships with laboratory animals, requires a 
conservative attitude toward new antibiotics development.  This attitude places limits on 
the justificatory role of demand in determining whether a particular research project 
meets the conditions for morally justified research, as defined by Rollin’s utilitarian 
principle.     
Identifying the Scope of the Problem 
Antibiotic resistant microbes are a major public health concern, and medical practitioners 
are currently calling for newer and more potent antibiotics, despite the scientific 
challenges of developing these products and the low rate of return for pharmaceutical 
companies.  Many factors lead to the existence of antibiotic resistant microbes, and there 
is significant empirical data suggesting that human prescribing practices are a major 
contributor to this phenomenon.  Laboratory animals endure great suffering and death in 
order for antibiotic drugs to reach the market, and it seems that the pursuit of new 
pharmaceutical products without comparable or even greater emphasis on changing 
dysfunctional human activities is a violation of the social contract with animals.  This 
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contract is apparent in both the companion and husbandry sector of human-nonhuman 
relationships, and properly belongs in the research arena as well. 
 In this paper, I will focus on a particular area of pharmaceutical research, the 
development of new antibiotics.  I will first present the theoretical background of the 
argument that the social contract with companion and agricultural animals also applies to 
laboratory animals, and that the social contract should include cultivation of a 
conservative attitude toward using animal products.  I will then provide empirical 
evidence to support the claim that the demand for new pharmaceuticals is artificially 
high, and that human behavior is a significant cause of the need for new antibiotics.  
Finally, I will argue that the conservative attitude inherent in the social contract requires 
us to make an effort to address the human causes of antibiotic resistant diseases, rather 
than subjecting laboratory animals to painful and stress-inducing procedures in order to 
meet this artificial demand for new antibiotics. 
Pharmaceutical Research and the Utilitarian Principle 
Bernard Rollin argues that laboratory animal research should conform to the utilitarian 
principle, which requires that “the benefit to humans (or humans and animals) clearly 
outweighs the pain and suffering experienced by the experimental animals.”1 Rollin 
states, however, that it is impossible to use the utilitarian principle in evaluating drug 
research, as there is no way of knowing when a given chemical is likely to be of 
therapeutic value.  In this section, we will consider some implications of the utilitarian 
principle in light of the statistical realities of antibiotics development and argue that the 
utilitarian principle, although helpful, is not sufficient for evaluating the moral 
appropriateness of antibiotic development research.   
Despite the outcries of abolitionists, not all animal research is unjustifiable, and some 
laboratory animal suffering is justified under ideal conditions.    Applying the utilitarian 
principle to pharmaceutical research ought to require that we consider the extent to which 
demand for new pharmaceuticals is artificially increased by the irresponsible practices of 
both medical professionals and consumers, as assessing this factor is critical to evaluating 
the legitimacy of the necessary animal suffering involved in new research projects.  This 
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becomes difficult when evaluating the demand for new antibiotics, in light of the 
prevalence of infectious diseases, which kill approximately 14 million people per year.2  
Many infectious diseases are exceedingly uncomfortable and lead to a significant amount 
of human suffering.  In addition, current literature indicates the proliferation of ever 
stronger strains of microbes, many of which are resistant to all but the newest and 
strongest antibiotics available.  Thus, we are easily influenced by the reality of mass 
human suffering associated with antibiotic resistant infections. 
Although we are compelled to consider dysfunctional human behavior in evaluating 
antibiotic development, it is not clear that we can do this effectively by applying the 
utilitarian principle.  The utilitarian principle does not allow for secondary considerations 
such as the source of demand for a product.3  By focusing on the balance between 
suffering and likely benefit, the utilitarian principle is an effective way to limit research 
to that which is truly necessary, but it fails to account for the dysfunctional causes of the 
necessity that it evaluates.  For example, the utilitarian principle might allow for 
development of a new antibiotic to treat tuberculosis, provided that the benefit is likely to 
exceed the animal suffering associated with the drug’s development.  However, the 
utilitarian principle lacks a mechanism for considering that a significant source of need 
for new antibiotics to treat tuberculosis is human-caused.  Many tuberculosis sufferers 
fail to complete their treatment regiments as directed, leading to the need for a second 
round of antibiotics that are much stronger.  Inadequate exposure in the first treatment 
cycle allows microbes to develop a resistance to the initial treatment regiment, and an 
antibiotic resistant microbe is created.  The utilitarian principle has no means for taking 
facts of this sort into consideration.   
We might also consider some implications of applying the utilitarian principle to 
pharmaceutical research.  Rollin cites statistics indicating that the ratio of beneficial 
substances to substances that are tested ranges from one in ten thousand to one in one 
hundred thousand.4  Even a conservative estimate of one in five thousand indicates that 
numerous instances of animal suffering and death are for no identifiable purpose, other 
than the exceedingly unlikely possibility that testing will result in a marketable substance.  
A .02% success rate does not seem to meet the requirements of the utilitarian principle, 
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even without the additional considerations that we are suggesting.  We have some reason 
to believe that the utilitarian principle does support a significant reduction in 
development of new antibiotics, simply due to the exceedingly unlikely possibility that 
the associated suffering will lead to any measurable benefit.   
It is noteworthy that a lack of basic understanding of infectious diseases has been cited as 
a significant contributor to the lack of success in developing new antibiotics.5  Most 
currently used antibiotics were developed in the 1970’s, and no new class of antibiotics 
was discovered during the 1970’s, ‘80s, and ‘90s.  One hypothesis for resolving this issue 
is that greater knowledge of systems biology would be helpful in improving this abysmal 
record.  Subjecting animals to painful testing procedures is difficult to justify when 
researchers lack the relevant knowledge of infectious diseases that would make their 
research more productive.  Obtaining such knowledge would likely reduce the number of 
failed drug trials, resulting in a net reduction in animal suffering and allowing some 
pharmaceutical research to be justified by the utilitarian principle.  Until such knowledge 
is acquired, however, it is not clear what percentage of antibiotics research projects are 
justified, regardless of the potential benefit that a particular project might have.  It seems 
that the utilitarian principle is somewhat inadequate in determining the moral 
appropriateness of a particular research project, which leads to the necessity of the social 
contract model in evaluating laboratory animal research.       
The Social Contract and the Conservative Attitude 
The social contract is significant in defining the parameters of appropriate treatment for 
both companion animals and agricultural animals.  It seems that the social contract 
equally applies to laboratory animals, due to a similarly reciprocal relationship.  The 
social contract requires not only a certain level of treatment and respect for animals, but 
also a conservative attitude toward use of animal products.  In this section, we will 
consider the feasibility of extending the social contract model to research animals, as well 
as supporting the importance of the conservative attitude that we are advocating.  
The social contract is relevant to human relationships with both companion and 
agricultural animals.  The social contract is essentially an agreement to treat others in a 
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certain way provided we are treated the same way in return.6  Although social contracts 
between humans and animals are implicit, they remain morally relevant.  In the case of 
companion animals, human beings receive numerous benefits as a direct result of having 
animals in their lives.  Our pets comfort and console us, providing unconditional love that 
few humans are capable of.  The significance of this is well-documented, as companion 
animals have been utilized in treatment of mental illnesses and credited with improving 
quality of life for invalids and the elderly.  This contribution is in addition to the more 
conventional benefits that many of us experience as a result of having pets.  The social 
contract entails that because animals have given up their wild natures in order to live with 
humans and provide benefits to us, we owe them a reciprocal degree of respect and 
appropriate treatment.   
The social contract is even more apparent, and perhaps more directly comparable to 
laboratory animals, in the institution of animal agriculture.  To state the nature of this 
version of the social contract as basically as possible, “we (humans) take care of the 
animals, and they take care of us.”  This means that the sacrifices associated with 
providing food, products, and a livelihood for humans necessarily entails a moral 
obligation to the animals.  Agricultural animals uphold their end of the social contract by 
providing us with nutritious food and useful products.  Our end of the social contract is to 
provide for the well-being and basic interests of agricultural animals, including adequate 
space, relevant enrichment, and attention to physical and psychological needs.7 
Both agricultural and companion animal relationships provide a comparable model for 
the relationship between human beings and laboratory animals.  In each of these arenas, 
animals have equally given up their wild natures and submitted to less than ideal 
conditions for the benefit of humans.  Humans are obligated, by the social contract, to 
make a concerted effort to meet the interests of the animals to the greatest extent possible.  
Certain degrees of suffering and mistreatment are not acceptable for any reason under the 
conditions of this contract.  Laboratory animals “take care of us” by providing life-saving 
and health improving products.  In much the same way, companion and agricultural 
animals provide a measureable benefit to humans.  As the social contract model suggests, 
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by choosing to have these types of relationships with animals, humans have entered into a 
social contract that requires a certain degree of treatment and care.   
The social contract requires that humans exhibit some degree of personal responsibility 
for their choices.  Rollin is highly critical of the current environment of irresponsible 
behavior toward pet animals and the resulting social institutions, which implicitly support 
an attitude of indifference toward animal interests.  One such example of this institutional 
support concerns the legislation designed to protect animals.  Although strides have been 
made, companion animals are still viewed primarily as property, and pet owners are 
granted the discretion to do as they wish with their property.  As a result, mutilation 
procedures like declawing and ear clipping are commonplace, and there are no legal 
repercussions for morally reprehensible acts like euthanizing a dog rather than paying to 
board it while the owner is on vacation.  These are clear examples of pet owners violating 
the basic rights of companion animals for their own convenience.  This lack of individual 
responsibility toward companion animals represents a clear violation of the social 
contract.  Humans are failing miserably in upholding their half of the contract, treating 
animals as mere property and means to our ends without regard for their most basic 
interests.   
The social contract also requires a conservative attitude toward the use of animal 
products.  A conservative attitude is a disposition of respect for animal sacrifices that 
allow for certain products to be available, and a disvaluing of purposeless waste.  The 
historical tendency of Native Americans to use all parts of the buffalo, as well as showing 
respect for the animal before killing it, is a paradigm example of this attitude (although 
the historical accuracy of this depiction is somewhat suspect).  Rollin’s discussion of the 
importance of personal responsibility in caring for pet animals is another example of the 
conservative attitude.  The conservative attitude is equally present in the social contract 
with agricultural animals.  Throwing away beef that could easily be eaten or wasting eggs 
on petty acts of vandalism, for example, would not be acceptable to most individuals who 
recognize the social contract.  If an animal suffers in order that we might benefit, it is 
reasonable to claim that humans have a moral obligation to honor and respect this 
sacrifice by not wasting animal products. 
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The conservative attitude toward companion and agricultural animals that we have 
identified is readily applicable to the social contract with laboratory animals that we are 
suggesting.  Consider the following example.  A beef cow is born and raised for the 
purpose of providing meat for humans.  Inevitably, some suffering or discomfort is likely 
in this animal’s life, despite our best effort to minimize such conditions.  In addition, this 
animal will eventually give its life so that we might live.  This sacrifice requires humans 
to be conscientious of our use of meat.  It would not be justifiable to increase meat 
production simply so that humans could waste meat products haphazardly.  What reason 
could we possibly give for facilitating such a practice?  Certainly any reason that might 
be offered would seem superficial and inadequate in light of the requisite animal 
suffering involved.  Analogously, a lab mouse might spend its natural life having new 
antibiotics tested on it.  This animal will also experience suffering despite our best effort 
to minimize such conditions.  Ultimately the animal will die, often at the conclusion of a 
research project and possibly as a direct result of the products tested upon it.  This animal 
has also made the “ultimate sacrifice” in order to benefit humans.  If we would not be 
justified in increasing meat production to facilitate irresponsible human behavior, it 
follows that we should not increase pharmaceutical testing in order to facilitate 
irresponsible behavior.  Such actions would equally represent a violation of the social 
contract with animals, and a failure to embrace the conservative attitude that the social 
contract requires.    
The Problem of Antibiotic Resistant Microbes 
Antibiotic resistant microbes are an increasingly significant concern in the medical 
community, and medical practitioners are calling for newer and more potent antibiotics.  
A brief review of the problem is therefore necessary if we are to understand the tendency 
to justify all antibiotic development research as necessary and the challenges associated 
with rejecting this justification.          
Concerns regarding antibiotic resistance emerged in the late 1990s,8 and it is typically 
cited as a major concern for medical practitioners.  Current statistics conclude that up to 
70% of all infectious bacteria are resistant to at least one commonly prescribed antibiotic, 
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and resistance is predicted to increase at 4% to 7% per year.  This problem is especially 
significant in the developing world, where it is often difficult to acquire large quantities 
of newer antibiotics.  This is compounded by the exceedingly difficult nature of antibiotic 
development, and the fact that many pharmaceutical companies to do not invest heavily 
in the development of new antibiotics, due to the low rate of return compared with drugs 
designed to treat long-term illnesses.   
Despite these challenges, many new antibiotics are being developed, with 7 new drugs 
receiving FDA approval in 2005, out of 81 approvals that same year.  In addition, 
approximately 18 new antibacterials are currently being tested.  These numbers seem 
insignificant until we consider the conservatively estimated success rate of .02% cited 
earlier.  The 7 drug approvals from 2005 are the result of 35,000 substances tested, while 
the 18 drugs currently in clinical trial might have as many as 90,000 unmarketable 
substances in their histories.  Based on the significant need for better antibiotics, 
however, many researchers are calling for new drugs to be developed despite these 
technical challenges. 9          
This cry for help is potentially problematic in light of the necessary animal suffering 
involved with such development activities and the well-documented correlation between 
medical practices, patient expectations, and overprescription of antibiotics.  An analysis 
of the irresponsible human practices fueling the need for newer antibiotics indicates that, 
although the current situation is somewhat supportive of a push for new antibiotics, much 
of the demand for stronger drugs is artificially enhanced and not morally justifiable. 
The Case for Human Behavior as a Cause of Artificial Demand 
There is a significant body of research which supports the claim that human practices of 
antibiotic prescription are excessive and dysfunctional, and that this is a significant 
contributor to the emergence of antibiotic resistant diseases, as well as a driving force in 
the call from the medical field for newer and more potent antibiotics.  Establishing that 
the demand for new antibiotics is artificially high requires that we draw a correlation 
between antibiotic resistance and dysfunctional human behaviors.  A majority of research 





medical practitioners, but a small percentage of this literature also considers the role of 
patient expectations as a relevant contributor to this issue.  We will consider this minority 
cause before turning to the role of physician behavior as the primary source of artificial 
demand for antibiotics. 
There is much evidence to support the claim that patient expectations are a significant 
contributor to the overprescription problem.  The most common manifestations of this 
problem are patient pressure exerted on doctors,10 patient assumptions that new and 
innovative antibiotics are always better and therefore desirable,11 and patient failure to 
follow treatment protocols.12  A 2007 survey of practitioners in Ireland supports the 
claim that patient behaviors are a contributing factor to overprescription of antibiotics, 
citing 54.7% of respondents who strongly agreed with the claim that patients often exp
a prescription for antibiotics, even when inappropriate.  22.7% of responding physicians
reported feeling under pressure to prescribe antibiotics for patients.13  This suggests that 
patients are not only making it clear that they expect to be given antibiotics, but that 
doctors are somewhat influenced by this expectation.   
Additional data also supports the claim that this pressure from patients is having an effect 
on doctor prescribing patters.  A 2007 article in Pharmacotherapy cited data from a 
survey of British patients with respiratory conditions, 72% of whom reported expecting 
antibiotic therapy.  The physicians who prescribed antibiotics reported that antibiotic 
therapy was only clinically indicated in 20% of the surveyed patients.  Another 20% of 
prescribing physicians reported writing a prescription in order to get the patient out of the 
office, rather than out of clinical necessity.14  It seems that patients seeking medical care 
have certain expectations for treatment, and physicians are responding in an effort to 
placate them.  Not only is this problematic in light of the emerging problem of antibiotic 
resistance, it is also a violation of the social contract with laboratory animals that we are 
advocating.  Reckless use of valuable medicines is not consistent with the conservative 
attitude required by the social contract, and statistical data provided supports the claim 
that a significant amount of current antibiotics use is frivolous, unnecessary, and 
responsive to dysfunctional social norms concerning medical care.  It would seem 
difficult to justify the development of new antibiotics without first addressing these 
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irresponsible social behaviors, and their measurable impact supports our claim that much 
of the demand for new antibiotics is artificial.   
If the problem of overprescription is to be addressed realistically, medical practitioners 
must also be held accountable for their contribution to this growing concern.  To some 
extent, the previously discussed problem of patient expectations is properly a problem 
with practitioners as well.  As professionals, their own ethic should require them to make 
responsible decisions, regardless of patient expectations which are often naïve and 
uninformed.  However, in an environment of fee-for-service medical care, it is difficult to 
remain unreceptive to patient expectations.  The line between patient and customer is 
blurry, making it difficult to separate between doing what is medically- indicated and 
satisfying the customer.    
Economic concerns aside, there are several prominent causes of overprescribing 
antibiotics that are more directly related to physician protocols.  The Journal of the 
Canadian Medical Association cites four causes of inappropriate prescribing behaviors 
among physicians.  Lack of physician knowledge, lack of experience, training 
environment that supports overprescribing, and avoidance of time-consuming patient 
education are all significant contributors to the problem of overprescribing antibiotics.15  
These essentially break down into two categories:  ignorance of relevant data, and 
influence of external factors. 
Ignorance-based causes of overprescribing are perhaps the easiest to resolve.  Lack of 
experience with prescribing is something of an unavoidable phenomenon, although the 
minimal time invested by medical schools to educate their students on responsible 
treatment protocols is a contributing factor,16 and adequate supervision of new physicians 
would likely alleviate most of this problem.  The greater concern in this category is the 
problem of genuine ignorance about proper prescribing protocols among knowledgeable 
medical professionals.  One source of this ignorance is poor judgment of treatment 
outcomes. 17  Many physicians are not very good at knowing what treatment is likely to 
succeed, so they err on the side of caution and prescribe antibiotics.  Other sources of 
genuine ignorance among physicians include not understanding what treatment protocols 
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are appropriate.  For example, despite numerous studies supporting the conclusion that 
antibiotics are not effective in treatment of the common cold, antibiotics are regularly 
prescribed for cold sufferers.18   This practice remains dangerously typical despite the 
obvious common-sense conclusion that antibacterials are not an effective treatment for a 
viral infection, which common colds tend to be.  Improper prescribing behavior of this 
kind is caused by physician reliance on outdated information, fear of undertreatment, and 
misguided beliefs.19  The belief that antibiotics will not hurt but may help is especially 
problematic, as it clearly represents a lack of understanding of the problem of 
overprescription, as well as a failure to display the conservative attitude that the social 
contract requires.   
Physicians are not solely responsible for the phenomenon of overprescription, and the 
irresponsible behavior of physicians is often externally influenced.  We have already 
mentioned the influence of patient expectations and economic considerations.  We might 
also mention one of the cited hypotheses that antibiotics are prescribed in order to avoid 
time-consuming patient education.  This is symptomatic of the nature of our medical 
system, which focuses on economic goals rather than optimal treatment protocols.  Many 
physicians are evaluated and paid at a piecemeal rate, and their self-interest motivates 
them to maximize the number of patients seen per day.  In addition, patient expectations 
require that medical practitioners explain complicated medical scenarios to individuals 
who may not be well equipped to understand, and in a manner that is sufficient to 
overcome a patient’s preconceived notion of what is necessary.  Quite simply, it is easier 
to write a prescription than it is to engage in this trying educational endeavor.   
The most significant external influence on physician prescribing behaviors is that of the 
pharmaceutical industry itself.  Due to the challenges of keeping physicians up to date on 
the latest medical research on pharmaceuticals, many physicians get a large portion of 
their continuing education directly from pharmaceutical representatives.  In addition, the 
close relationship between the industry and individual physicians can lead to a conflict of 
interest.  Many physicians receive personal benefits from prescribing as many antibiotics 
as possible, with higher compensation rates for new antibiotics.  Finally, the prevalence 
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of pharmaceutical advertising supports patient attitudes that antibiotic treatment is always 
preferable, and that unnecessary prescriptions do no harm.   
There are many additional issues that contribute to the problem of overprescribing 
antibiotics.  Our intention is simply to illustrate that the demand for new antibiotics is 
being affected by a wide variety of dysfunctional practices of both physicians and 
patients, and that the demand for new antibiotics is therefore somewhat artificial.  Much 
like the problems associated with companion animal treatment, many irresponsible 
individual activities in the medical field are being buttressed by the social institution of 
overprescription.  Just as animal shelters should be utilized conservatively so as to 
prevent reinforcing dysfunctional attitudes toward companion animals, development of 
new antibiotics should also be conservatively approached so as to encourage self-
correction of these problems and prevent the unjustified suffering of laboratory animals 
that would be necessary if the artificially high demand for new antibiotics were to be met. 
 
Application of the Formal Argument 
We have thus far presented the philosophical background supporting an extension of the 
social contract to research animals and argued that the social contract necessitates a 
conservative attitude toward the use of animal products.  We have utilized relevant 
empirical data to support the claim that the demand for new antibiotics is artificially 
enhanced by irresponsible human behaviors.  We now turn to a formalization of our main 
argument in an effort to clarify its conclusions.   
The following represents the argument presented in a basic format: 
1) The social contract requires a conservative attitude towards use of products that 
rely on animals, directly or indirectly, for their development. 
2) Personal and professional responsibility are important features of this 
conservative attitude, and failure to act as such is a violation of the social contract. 
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3) Demand for a product that is artificially increased by irresponsible human 
behaviors does not provide sufficient justification for animal suffering. 
4) The demand for new antibiotics has been artificially increased by irresponsible 
human behaviors, which manifest in the practice of overprescription. 
5) From 3 and 4, animal suffering for the purpose of developing new antibiotics is 
not justified solely by reference to the demand for new antibiotics.   
6) From 2 and 4, the call for new antibiotics and the practice of overprescription do 
not reflect the conservative attitude of personal and professional responsibility 
that is an important feature of the social contract. 
7) From 1 and 6, the call for new antibiotics and the practice of overprescription are 
violations of the social contract. 
Premise 1 assumes that the social contract applies to laboratory animals and that the 
conservative attitude is a key component of the social contract, as we argued earlier.  
Premise 2 is an articulation of what the conservative attitude entails and is based on 
extending Rollin’s claims regarding personal responsibility and companion animals to 
other areas of human-nonhuman relationships.  Premise 3 is perhaps the most 
controversial, relying on the content of Premises 1 and 2 in order to support the notion 
that personal responsibility and the social contract do not allow for demand to be 
haphazardly referenced as justification for certain actions that cause harm.  Premise 3 
also relies on common-sense notions of how valuable products should and should not be 
used.  Inclusion of the term “sufficient” is significant, and is intended to limit the 
influence of artificial demand for antibiotics without eliminating the relevance of 
legitimate demand.  The claim is simply that demand alone, if it is artificially enhanced, 
does not morally justify testing new antibiotics on animals.  Premise 4 is based on the 
empirical data presented which supports the claim that dysfunctional human behavior is 
increasing the need for new antibiotics.  We are left with three relatively uncontroversial 
conclusions, namely that animal suffering for the purpose of developing new antibiotics 
is not justified solely by reference to demand, that the call for new antibiotics and the 
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practice of overprescription are not consistent with the conservative attitude properly 
associated with the social contract, and that the call for new antibiotics and the practice of 
overprescription are violations of the social contract with research animals. 
We should note that this argument does not lead to the conclusion that no new antibiotics 
can ever be developed.  Our claim is simply that the appropriate conservative attitude 
toward antibiotic development, as necessitated by the social contract, does not allow us to 
justify developing new antibiotics solely on the basis of demand, since much of the 
demand is artificially influenced by irresponsible human behaviors.  At an absolute 
minimum, efforts should be made to address the problem of dysfunctional human 
behaviors before substantial investment in antibiotic development is undertaken.  
Antibiotic development is becoming increasingly difficult from a scientific standpoint, 
and it is in our interest to curtail the wasteful practices of patients and physicians so that 
future new antibiotics are not wasted without maximizing the utility of their potential.  
Animal interests aside, we have good pragmatic reasons to adopt the conclusions of this 
argument.  We also have good reasons, from the standpoint of animal rights, to adopt the 
conservative attitude necessitated by the social contract and apply it to evaluating new 
antibiotics development projects.   
Conclusion 
In the case of developing new antibiotics, once we incorporate the appropriate 
conservative attitude required by the social contract, the utilitarian principle does support 
a reduction in research on new antibiotics, at least until the problems of overprescription 
are addressed.  The challenge of applying the utilitarian principle in this area is that we 
are tempted to justify a great deal of suffering in order to allow for significant 
breakthroughs to take place.  This is not surprising in light of the prevalent devastation of 
infectious diseases worldwide.  However, based on the empirical data presented, the 
conservative attitude required by the social contract makes it difficult to justify a good 
deal of suffering that the utilitarian principle might have allowed us to overlook.  
Although the utilitarian principle is an important starting point for evaluating research, 
we should also consider the source of demand for new antibiotics by applying the 
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conservative attitude of the social contract.  This will result in more stringent criteria for 
morally justifiable antibiotics development research that utilizes animal testing, 
protecting laboratory animals from unjustifiable suffering.  It will also force both 
consumers and medical practitioners to be more cautious in their attitudes toward 
appropriate use of antibiotics.  By adopting the conservative attitude, both human and 
non-human may benefit.       
References 
Brehaut, Jamie.   “Do physician outcome judgments and judgment biases contribute to 
inappropriate use of treatments?” Implementation Science Vol.2  2007. 
Cadieux, Genevieve, Robyn Tamblyn, Dale Dauphinee, and Michael Libman.  “Predictors of 
inappropriate antibiotic prescribing among primary physicians” Canadian Medical 
Association Journal Oct. 9  2007. 
Cotter, M. and L. Daly.  “Antibiotic prescription practices of general practitioners” Irish Medical 
Journal, Vol. 100, Issue 9  2007. 
Ebert, Steven C.  “Factors contributing to excessive antimicrobial prescribing” Pharmacotherapy, 
Vol. 27, Issue 10, Part 2  2007. 
Kumble, K.D.  “Anti-Bacterial Drug Discovery Using Systems Biology”, Mini-Reviews in 
Medicinal Chemistry Vol.6, No.11  2006. 
Liu, J. and H.P. Ren.  “Tuberculosis:  Current Treatment and New Drug Development” Anti-
Infective Agents in Medicinal Chemistry Vol. 5, No. 4  2006. 
Rollin, Bernard.  Animal Rights and Human Morality (Amherst, NY:  Prometheus, 2006). 
Rollin, Bernard.  Farm Animal Welfare (Ames:  Iowa Stae Press, 1995). 
Sharma, Rashmi.  “Antibacterial resistance:  Current problems and possible solutions” Indian 
Journal of Medical Sciences, Vol. 59, Issue 3  2005. 
Simasek, Madeline and David A. Blanding.  “Treatment of the Common Cold” American Family 
Physician  Vol. 75, No. 4  2007. 
 
 
1 Bernard Rollin, Animal Rights and Human Morality (Amherst, NY:  Prometheus, 2006)  183. 
2 K.D. Kumble, “Anti-Bacterial Drug Discovery Using Systems Biology”, Mini-Reviews in Medicinal 
Chemistry Vol.6, No.11  2006:  1275. 
3 Based on Rollin’s discussion of how this principle is applied, from Animal Rights and Human Morality. 
4 Bernard Rollin, Animal Rights and Human Morality (Amherst, NY:  Prometheus, 2006)  279. 
 
5 K.D. Kumble, “Anti-Bacterial Drug Discovery Using Systems Biology” Mini-Reviews in Medicinal 
Chemistry Vol.6, No.11  2006:  1276. 
16 
 
                                                                                                                                                 
 
6Bernard Rollin, Animal Rights and Human Morality (Amherst, NY:  Prometheus, 2006)  51. 
 
7 See Rollin’s Farm Animal Welfare. 
8 Rashmi Sharma, “Antibacterial resistance:  Current problems and possible solutions” Indian Journal of 
Medical Sciences, Vol. 59, Issue 3  2005:  120. 
9 See Sharma 2005, Kumble 2007, Liu and Ren 2006, and Ebert 2007. 
10 M. Cotter and L. Daly “Antibiotic prescription practices of general practitioners” Irish Medical Journal, 
Vol. 100, Issue 9  2007:  598. 
11 Steven C. Ebert “Factors contributing to excessive antimicrobial prescribing” Pharmacotherapy, Vol. 27, 
Issue 10, Part 2  2007:  1275. 
12 J. Liu and H.P. Ren “Tuberculosis:  Current Treatment and New Drug Development” Anti-Infective 
Agents in Medicinal Chemistry Vol. 5, No. 4  2006:  331. 
13 M. Cotter and L. Daly “Antibiotic prescription practices of general practitioners” Irish Medical Journal, 
Vol. 100, Issue 9  2007:  598. 
14 Steven C. Ebert “Factors contributing to excessive antimicrobial prescribing” Pharmacotherapy, Vol. 27, 
Issue 10, Part 2  2007:  1275. 
15 Genevieve Cadieux, et al “Predictors of inappropriate antibiotic prescribing among primary physicians” 
Canadian Medical Association Journal  Oct. 9  2007:  877. 
16 Steven C. Ebert “Factors contributing to excessive antimicrobial prescribing” Pharmacotherapy, Vol. 27, 
Issue 10, Part 2  2007:  1274. 
17 Jamie Brehaut “Do physician outcome judgments and judgment biases contribute to inappropriate use of 
treatments?” Implementation Science Vol.2  2007:  20. 
18Madeline Simasek and David A. Blanding “Treatment of the Common Cold” American Family Physician  
Vol. 75, No. 4  2007:  517. 
19 Steven C. Ebert “Factors contributing to excessive antimicrobial prescribing” Pharmacotherapy, Vol. 27, 
Issue 10, Part 2  2007:  1285. 
 
